Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02579811
Other study ID # CASE7815
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 30, 2015
Est. completion date June 20, 2023

Study information

Verified date June 2023
Source Case Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Axitinib is a drug which is approved by the FDA for patients with advanced kidney cancer who have already received some treatment. It works by reducing blood flow to a tumor. Axitinib is normally give at 5mg twice per day and sometimes this dose is increased if patients tolerate it. The purpose of this study is to figure out a different way to decide which dose of axitinib each patient should receive based on the side effects they experience.


Description:

Primary objective To determine whether axitinib given on an individualized dose/schedule for metastatic renal cell carcinoma following immunotherapy with PD-1 and PD-L1 Inhibitors leads to improved progression-free survival (PFS). Secondary objectives: 1. To characterize the objective response rates in patients given axitinib on an individualized dose/schedule. 2. To evaluate the tolerability and safety of an alternative method of axitinib titration. 3. To characterize the anti-tumor effect, as measured by change in tumor burden per RECIST 1.1, of axitinib titration performed after initial RECIST PD on axitinib.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 20, 2023
Est. primary completion date August 21, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed, locally recurrent or metastatic clear cell renal cell carcinoma - Has received one prior systemic therapy regimen for Metastatic Renal Cell Carcinoma (mRCC) directed against PD-1 and/or PD-L1 which must have been the most recent regimen - Prior high-dose interleukin-2 therapy is permitted in addition to anti-PD(L)1 therapy, but is not required - Prior bevacizumab or Vascular Endothelial Growth Factor (VEGF) Tyrosine Kinas Inhibitor (TKI) is permitted either in combination with anti-PD(L)1 therapy OR as monotherapy when given PRIOR to anti-PD(L)1 therapy - Prior treatment with combined ipilimumab and nivolumab is permitted - Prior axitinib in any setting is not permitted - A minimum of two weeks since last dose of most recent renal cell cancer therapy assuming resolution of clinically significant treatment-related toxicities to grade 1, baseline, or controlled with supportive medications - Evidence of measurable disease per RECIST 1.1. - Karnofsky performance status = 70 %. - Adequate organ function as defined by: - Absolute neutrophil count (ANC) =1,000/µL - Platelets =100,000/µL - Hemoglobin =9.0 g/dL - Serum calcium =12.0 mg/dL - Serum creatinine =2.0 x Upper Limit of Normal (ULN) - Total serum bilirubin =1.5 x ULN - SGOT=2.5 x ULN and Serum Glutamic Pyruvic Transaminase (SGPT) =2.5x ULN - Signed informed consent and willingness/ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures Exclusion Criteria: - Non clear cell Renal Cell Carcinoma (RCC) - Major surgery within 4 weeks of starting the study treatment. - Radiation therapy within 2 weeks of starting the study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated. - NCI CTCAE Version 4.03 grade 3 hemorrhage within 4 weeks of starting the study treatment. - Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack. - Ongoing cardiac dysrhythmias of NCI CTCAE Version 4.03 grade =2. Controlled atrial fibrillation is permitted. - Uncontrolled hypertension (>160/100 mm Hg despite optimal medical therapy) - Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. QOL, and imaging trials, are allowed. - Pregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study. - Uncontrolled Central Nervous System (CNS) metastases. Patients are considered to have controlled CNS metastases (and thus eligible) if they have completed local therapy (XRT and/or surgery) and are off steroids with clinical and radiographic stability 3 months from the end of CNS-directed therapy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Axitinib
The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria

Locations

Country Name City State
United States Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio
United States The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus Ohio
United States City of Hope Comprehensive Cancer Center Duarte California
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median Progression-free Survival The primary endpoint of progression-free survival in months (per per RECIST v1.1 criteria) will be estimated using the Kaplan-Meier method. Summary statistics will be provided along with 95% confidence intervals. Up to 18 months
Secondary Patients With Complete Response Tumor Response, defined as overall confirmed objective response, is confirmed complete response (CR) according to the RECIST 1.1 criteria. RECIST 1.1: Complete response (CR) is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Up to 4 months of treatment and approximately 1 year of follow-up
Secondary Patients With Partial Response Tumor Response, defined as overall confirmed objective response, is confirmed complete response (CR) according to the RECIST 1.1 criteria. RECIST 1.1: Partial response (PR) is defined as a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Up to 4 months of treatment and approximately 1 year of follow-up
Secondary Objective Response Rate (ORR) ORR as defined by Recist V. 1.1. ORR = (CR + PR) Up to 4 months of treatment and approximately 1 year of follow-up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02664883 - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed NCT03229278 - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma Phase 1
Completed NCT01462214 - Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer Phase 1/Phase 2
Completed NCT02555748 - Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Phase 4
Completed NCT02899078 - Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT00670748 - Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer Phase 2
Completed NCT01829841 - A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer Phase 2
Active, not recruiting NCT01767636 - Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Phase 2
Terminated NCT02542202 - Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer N/A
Completed NCT02626130 - Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer Early Phase 1
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Active, not recruiting NCT01590069 - Aerosolized Aldesleukin in Treating Patients With Lung Metastases Phase 1
Recruiting NCT01884961 - Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 Phase 2
Completed NCT02599194 - 18F-FSPG PET/CT for Cancer Patients on Therapy Phase 2
Completed NCT01246843 - Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib N/A
Completed NCT01258348 - A Phase 1b Trial in Patients With Renal Cell Cancer Phase 1
Completed NCT00428220 - A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. N/A
Active, not recruiting NCT03092856 - Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Phase 2
Completed NCT02843607 - Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer Phase 1/Phase 2
Completed NCT02318771 - Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer Phase 1